KR20070078107A - Lactic acid bacteria preventing and treating allergic diseases - Google Patents
Lactic acid bacteria preventing and treating allergic diseases Download PDFInfo
- Publication number
- KR20070078107A KR20070078107A KR1020060007968A KR20060007968A KR20070078107A KR 20070078107 A KR20070078107 A KR 20070078107A KR 1020060007968 A KR1020060007968 A KR 1020060007968A KR 20060007968 A KR20060007968 A KR 20060007968A KR 20070078107 A KR20070078107 A KR 20070078107A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- lactic acid
- acid bacteria
- lactobacillus plantarum
- lactobacillus
- Prior art date
Links
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B62—LAND VEHICLES FOR TRAVELLING OTHERWISE THAN ON RAILS
- B62M—RIDER PROPULSION OF WHEELED VEHICLES OR SLEDGES; POWERED PROPULSION OF SLEDGES OR SINGLE-TRACK CYCLES; TRANSMISSIONS SPECIALLY ADAPTED FOR SUCH VEHICLES
- B62M1/00—Rider propulsion of wheeled vehicles
- B62M1/12—Rider propulsion of wheeled vehicles operated by both hand and foot power
-
- A—HUMAN NECESSITIES
- A63—SPORTS; GAMES; AMUSEMENTS
- A63B—APPARATUS FOR PHYSICAL TRAINING, GYMNASTICS, SWIMMING, CLIMBING, OR FENCING; BALL GAMES; TRAINING EQUIPMENT
- A63B23/00—Exercising apparatus specially adapted for particular parts of the body
- A63B23/035—Exercising apparatus specially adapted for particular parts of the body for limbs, i.e. upper or lower limbs, e.g. simultaneously
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B62—LAND VEHICLES FOR TRAVELLING OTHERWISE THAN ON RAILS
- B62M—RIDER PROPULSION OF WHEELED VEHICLES OR SLEDGES; POWERED PROPULSION OF SLEDGES OR SINGLE-TRACK CYCLES; TRANSMISSIONS SPECIALLY ADAPTED FOR SUCH VEHICLES
- B62M3/00—Construction of cranks operated by hand or foot
- B62M3/14—Hand-grips for hand-operated cranks
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B62—LAND VEHICLES FOR TRAVELLING OTHERWISE THAN ON RAILS
- B62M—RIDER PROPULSION OF WHEELED VEHICLES OR SLEDGES; POWERED PROPULSION OF SLEDGES OR SINGLE-TRACK CYCLES; TRANSMISSIONS SPECIALLY ADAPTED FOR SUCH VEHICLES
- B62M9/00—Transmissions characterised by use of an endless chain, belt, or the like
- B62M9/04—Transmissions characterised by use of an endless chain, belt, or the like of changeable ratio
- B62M9/06—Transmissions characterised by use of an endless chain, belt, or the like of changeable ratio using a single chain, belt, or the like
Landscapes
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Combustion & Propulsion (AREA)
- Transportation (AREA)
- Mechanical Engineering (AREA)
- Health & Medical Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
도1은 락토바실러스 속 특이 프라이머를 이용한 연쇄중합반응 결과를 보여주는 그림이다.1 is a diagram showing a chain polymerization result using a specific primer of the genus Lactobacillus.
도2는 락토바실러스 플랜타럼 K8의 구성성분이 비장세포의 싸이토카인 발현에 미치는 영향을 보여주는 그림이다.Figure 2 shows the effect of the components of Lactobacillus plantarum K8 on the cytokine expression of splenocytes.
과민증 (anaphylaxis), 알러지성 비염 (allergic rhinitis), 천식 (asthma) 아토피성 피부염 (atopic dermatitis), 두드러기 (urticaria)와 같은 IgE 매개 알러지성 질환은 비만세포와 산성백혈구 (eosinophil)가 중요한 역할을 한다.IgE-mediated allergic disorders such as anaphylaxis, allergic rhinitis, asthma atopic dermatitis, and urticaria play an important role in mast cells and acidic leukocytes (eosinophil) .
IgE을 생산하는 면역반응은 Th0 세포를 Th2 세포로 분화시키는 신호와 B 면역세포로 하여금 IgE를 생산하도록 하는 Th2 세포로부터 생산되는 싸이토카인 등이 매우 중요하다. IL-4. -5, -9, -10, -13과 같은 싸이토카인은 전술한 바와 같이 B 면역세포로 하여금 IgE를 생산하도록 하며 Th0 세포가 Th2 세포로 분화하는 것을 유도한다.The IgE-producing immune response is very important for signals that differentiate Th0 cells into Th2 cells and cytokines produced from Th2 cells that cause B immune cells to produce IgE. IL-4. Cytokines such as -5, -9, -10 and -13 allow B immune cells to produce IgE as described above and induce Th0 cells to differentiate into Th2 cells.
Th1과 Th2 면역반응의 평형을 통해 알레르기를 치료하는 시도가 있다. 첫째는 알러젠을 낮은 농도로부터 점차적으로 투여하는 감작 (hyposensitization)을 통해 알러젠에 의한 면역반응을 Th2에서 Th1으로 유도하여 IgE 대신 IgG를 생산하는 방법이다. 두 번째는 Th0 세포가 Th1 세포로 분화하도록 IFN-γ, IL-10, IL-12, TGF-β 등이나 Th1 자극 면역강화제 (adjuvant)를 투여하는 방법 등이 있다.Attempts have been made to treat allergies by balancing Th1 and Th2 immune responses. The first is a method of producing IgG instead of IgE by inducing an allergen-induced immune response from Th2 to Th1 through hypoxitization, in which allergens are gradually administered from low concentrations. Second, IFN- [gamma], IL-10, IL-12, TGF- [beta], etc., or Th1 stimulating adjuvant are administered to differentiate Th0 cells into Th1 cells.
신생아 시기의 감염과 알레르기 질환과는 역비례 관계가 있다 (hygiene hypothesis, Strachan, D. P., 1989, Hay fever, hygiene and household size. BMJ 299:1259-1260). 신생아의 면역체계 완성에 중요한 병원성 미생물에 의한 감염 감소는 면역체계의 불균형을 해소하지 못 하는 것으로 알려져 있다. 실제로 태아 및 신생아 기간은 Th2 면역반응 쪽으로 편향되어 있는 것으로 알려져 있다.There is an inverse relationship between infection and allergic disease in the neonatal period (hygiene hypothesis, Strachan, D. P., 1989, Hay fever, hygiene and household size.BMJ 299: 1259-1260). Reduction of infection by pathogenic microorganisms, which are important for neonatal immune system completion, is not known to resolve immune system imbalances. Indeed fetal and neonatal periods are known to be biased towards the Th2 immune response.
유산균은 사람의 면역반응을 조절하고 장관의 항상성 (homeostasis)을 유지하는 데 도움을 주고 최근에는 항원제시세포의 일종인 수지상 세포 (dendritic cell)를 자극하여 Th1 면역반응을 유도하여 알레르기 질환의 예방 및 치료에 기여할 수 있는 것으로 알려져 있다 (Mohamadzadeh, M. et al., 2005, Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. PNAS. 102:2880-2885.). 실제로 임산부와 신생아의 Lactobacillus와 Bifidobacterium 속 균주의 섭취를 통해서 아토피 피부염이 완화되었다는 보고 등이 있다 (Rosenfeldt, V. et al., 2003. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J. Allergy Clin. Immunol. 111:389-395).Lactobacillus helps to regulate human immune response and maintain intestinal homeostasis, and recently stimulates dendritic cells, a kind of antigen presenting cells, to induce Th1 immune response to prevent allergic diseases and It is known to contribute to treatment (Mohamadzadeh, M. et al., 2005, Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. PNAS. 102: 2880-2885.). Indeed, there have been reports of atopic dermatitis alleviated through the ingestion of Lactobacillus and Bifidobacterium strains in pregnant women and newborns (Rosenfeldt, V. et al., 2003. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J. Allergy Clin. Immunol. 111: 389-395).
유산균의 건강증진 효과는 속 (genus)과 종 (species)의 일반적 특징이라기보다는 균주 (strain) 특이적이다 (Report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food, London Ontario, Canada, 2002). 따라서 본 발명은 Th2 싸이토카인의 수치를 낮추고 Th1 싸이토카인의 수치를 높여 Th1/Th2 면역반응의 평형을 통해 아토피성 피부염 등의 IgE 매개 알레르기성 질환 예방 및 치료를 위한 락토바실러스 플랜타럼 K8 (Lactobacillus plantarum K8) 및 그 파쇄물을 제공하는 것이다.The health-promoting effects of lactic acid bacteria are strain-specific rather than general features of genus and species (Report of a joint FAO / WHO working group on drafting guidelines for the evaluation of probiotics in food, London Ontario , Canada, 2002). Therefore, the present invention lowers the level of Th2 cytokine and raises the level of Th1 cytokine to balance and prevent IgE-mediated allergic diseases such as atopic dermatitis through the equilibrium of Th1 / Th2 immune responses, Lactobacillus plantarum K8 And to provide a crush.
본 발명의 또 다른 목적은, 락토바실러스 플랜타럼 K8을 함유하는 건강기능성 식품을 제공하는 것이다.Still another object of the present invention is to provide a health functional food containing Lactobacillus plantarum K8.
본 발명의 또 다른 목적은, 락토바실러스 플랜타럼 K8을 이용하여 발효한 식품을 제공하는 것이다.Still another object of the present invention is to provide a food fermented using Lactobacillus plantarum K8.
각지에서 수집한 김치에서 배지의 pH를 낮추어 황색을 띠는 집락을 선발하여 속 특이 프라이머 (genus-specific primer)를 이용한 연쇄중합반응에서 중합산물을 형성하는 락토바실러스 속 김치유산균을 선발하였다.Kimchi Lactobacillus of Lactobacillus, which forms a polymerization product in a chain polymerization reaction using genus-specific primers, was selected by lowering the pH of the medium from Kimchi collected from various places.
선발한 김치유산균에서 Th2 면역반응으로 편향된 ovalbumin 면역제시 마우스의 비장세포에서 Th1 cytokine-12를 발현하고 Th1 cytokine-4를 억제하는 유산균을 선발하였다.Lactobacillus expressing Th1 cytokine-12 and inhibiting Th1 cytokine-4 were selected from splenocytes of mice with ovalbumin immunity biased by Th2 immune response.
유산균의 구성성분을 각각 분리하여 상기와 같이 싸이토카인의 발현 양상을 조하여 유산균의 구성성분 중 하나인 lipoteichoic acid가 싸이토카인 평형을 이룰 수 있도록 Th1 면역반응을 유도하는 것을 확인하였다.It was confirmed that the components of lactic acid bacteria were isolated to adjust the expression patterns of cytokines as described above to induce Th1 immune response so that lipoteichoic acid, one of the components of lactic acid bacteria, could achieve the cytokine equilibrium.
상기 김치유산균의 형태적, 생리적 특징을 조사하여 락토바실러스 플랜타럼 K8으로 명명하였으며 2006년 1월 20일부로 한국생명공학연구원 생물자원센터 (KCTC)에 기탁하여 본 발명을 완성하였다 (기탁번호 KCTC 10887BP).The morphological and physiological characteristics of the Kimchi Lactobacillus were investigated and named as Lactobacillus plantarum K8. On January 20, 2006, it was deposited with the Korea Institute of Bioscience and Biotechnology (KCTC) to complete the present invention (Accession No. KCTC 10887BP). .
본 발명에 따른 김치유산균의 특성은 다음과 같다.Characteristics of kimchi lactic acid bacteria according to the present invention are as follows.
1. 균의 형태1. Morphology
MRS 한천평판배지에서37℃에서 2일간 배양하였을 때,When incubated for 2 days at 37 ℃ in MRS agar plate medium,
① 균의 형태: 단간균① Type of bacteria: Bacillus
② 운동성: 없음② Mobility: None
③ 포자형성능: 없음③ Spore Formation Capacity: None
④ Gram staining: 양성④ Gram staining: positive
2. 생리적 특징2. Physiological Features
① 15℃에서 생육: +① Growth at 15 ℃: +
② 45℃에서 생육: +② Grown at 45 ℃: +
③ 젖산 생산 및 형태: DL형 젖산③ Lactic acid production and form: DL-type lactic acid
④ 당발효 시험④ Sugar fermentation test
아미그달린:+Amigdalin: +
아라비노스:+Arabinos: +
셀로바이오스:-Cellobiose:-
에스큘린: +Esculin: +
글루코네이트:Gluconate:
만니톨:+Mannitol: +
멜레지토스:+Melegitos: +
멜리바이오스:+Mellibiose: +
라피노스:+Rafinos: +
리보스:+Ribose: +
솔비톨:+Sorbitol: +
설탕:+Sugar: +
자일로스:-Xylose:-
이와 같은 균의 형태적, 생리적 및 생장 특성에 근거하여 본 발명의 균주는 락토바실러스 플랜타럼 K8로 명명하였다.Based on the morphological, physiological and growth characteristics of such bacteria, the strain of the present invention was named Lactobacillus plantarum K8.
이하 실시예를 통하여 본 발명을 보다 상세히 설명하고자 한다.Through the following examples will be described the present invention in more detail.
실시예 1Example 1
김치유산균 수집Kimchi Lactobacillus Collection
각지에서 수집한 김치에서 찌꺼기를 거르고 멸균생리식염수에 적절히 희석하여 pH 지시약이 첨가된 평판측정용 한천배지 (효모 추출물 0.25중량%, 프로테오스 펩톤 No.3 0.5 중량%, 포도당 0.1중량%, 트윈 80 0.1중량%, L-씨스테인 0.01중량%, 아가 1.5 중량%, 브로모크레졸 퍼플 0.005%)에 집락을 배양하였다. 배지의 pH를 낮추어 황색을 띠는 집락을 선발하여 속 특이 프라이머 (genus-specific primer, Dubernet, et al., 2002. A PCR-based method for identification of lactobacillus at the genus level. FEMS Microbiol. Letts. 214:271-275) (표1)를 이용한 연쇄중합반응에서 중합산물 (250 base-pairs)을 형성하는 락토바실러스 속 김치유산균을 선발하였다 (도1).Agar plates for measurement of flattened debris from kimchi collected from all over the country, diluted with sterile saline solution and added with pH indicator (0.25% yeast extract, 0.5% by weight of proteose peptone No.3, 0.1% by weight of glucose, twin Colonies were cultured in 80% by weight, 0.01% by weight of L-cysteine, 1.5% by weight of agar, and 0.005% of bromocresol purple). The PCR-based method for identification of lactobacillus at the genus level.FEMS Microbiol.Letsts 214 by selecting yellow colonies by lowering the pH of the medium. : 271-275) Kimchi lactic acid bacteria of the genus Lactobacillus forming polymerized products (250 base-pairs) were selected in the chain polymerization reaction using (Table 1) (Fig. 1).
실시예 2Example 2
Th2 편향 비장세포의 싸이토카인에 미치는 김치유산균의 영향Effect of Kimchi Lactobacillus on Cytokines in Th2-biased Spleen Cells
Th1 cytokine IL-12 (p70)와 Th2 cytokine IL-4의 발현에 미치는 유산균의 영향을 조사하기 위하여 ovalbumin을 제시하여 (primed) Th2 면역으로 편향된 비장세포를 사용하였다. BALB/c mouse에 ovalbumin을 흡착한 Al(OH)3을 0일 및 6일에 복강 주사하였다. 13일 째에 비장을 제거하고 단일세포로 분리한 후, 적혈구를 용혈시켜 비장세포를 얻어 2×106 cell/ml의 수로 10% FBS 및 항생제가 첨가된 RPMI 배지 (HyClone)에 현탁하였다. well 당 2×105 cell을 심고 ovalbumin 1mg/ml, 유산균 108 cfu/well을 처리하여 3일간 배양하였다. 배양 상징액을 회수하여 IL-12, IL-4를 ELISA 방법으로 측정하였다.To investigate the effect of lactic acid bacteria on the expression of Th1 cytokine IL-12 (p70) and Th2 cytokine IL-4, ovalbumin was used (primed) and splenocytes deflected by Th2 immunity were used. O (Al) 3 adsorbed ovalbumin to BALB / c mice was intraperitoneally injected on day 0 and day 6. On the 13th day, the spleen was removed and separated into single cells. The red blood cells were hemolyzed to obtain splenocytes and suspended in RPMI medium (HyClone) to which 10% FBS and antibiotics were added in a number of 2 × 10 6 cells / ml. 2 × 10 5 cells per well were planted and treated with ovalbumin 1mg / ml and
Lactobacillus plantarum K8이 IL-12를 가장 강하게 유도하였다. 각 균주의 IL-12와 IL-4 유도능은 서로 달랐으며 IL-12 유도능이 큰 유산균은 IL-4 발현을 억제하는 경향을 나타내었다. Lactobacillus plantarum K8 induced IL-12 most strongly. IL-12 and IL-4 inducing ability of each strain was different from each other, and lactic acid bacteria with high IL-12 inducing ability showed a tendency to inhibit IL-4 expression.
실시예 3Example 3
3-1) 유산균 구성성분 분리3-1) Isolation of Lactic Acid Bacteria Components
Bacterial subcellular fractions는 Roman Dziarski (Methods in enzymology, Academic Press, San Diego, 1994, pp255-260) 등이 사용한 방법을 이용하였다. 요약을 하면, Lactobacillus plantarum K8을 optimal density (OD) 620nm에서 mid logarithmic phase 까지 배양한 후 세포를 ice ethanol bath에 넣어 4℃까지 cooling 시켰다. 원심분리기(6,000xg, 4℃)를 이용하여 세포를 harvest하고, saline으로 re-suspension 시킨 후 100℃에서 20분간 boiling 시켰다. heat-killed bacterial 세포를 다시 원심분리하여 모은 후 saline으로 두 번 distilled water (DW)로 한번 그리고 acetone으로 3번 세척하였다. 37℃에서 heat-killed 된 bacterial 세포를 건조시킨 후 'heat-killed bacterial cells'로 사용하였다. Bacterial subcellular fractions were used by Roman Dziarski (Methods in enzymology, Academic Press, San Diego, 1994, pp255-260). In summary, Lactobacillus plantarum K8 was incubated at an optimal density (OD) of 620nm to mid logarithmic phase, and the cells were cooled to 4 ° C in an ice ethanol bath. Cells were harvested using a centrifuge (6,000xg, 4 ° C), re-suspensioned with saline and boiled at 100 ° C for 20 minutes. Heat-killed bacterial cells were collected by centrifugation again, washed twice with saline twice with distilled water (DW) and three times with acetone. After drying the heat-killed bacterial cells at 37 ℃ was used as 'heat-killed bacterial cells'.
건조된 heat-killed bacterial 세포를 ice cold water로 suspension 시킨 후 0.1mm glass beads를 사용하여 분쇄하였다. 파쇄되지 않은 세포는 원심분리 (1,500xg, 4℃, 10분)를 사용하여 제거시키고, 파쇄된 세포만을 'crude extract'로 사용하였다. 원심분리 (6,500xg, 4℃, 30분)를 통하여 crude extract를 침전 시킨 후 침전물을 DW로 3번 세척하였다. 이 후 ribonuclease (100ug/ml)과 deoxyribonuclease (50ug/ml)를 첨가하여 37℃에서 18시간동안 incubation 시켰다. 6,500xg에서 30분간 원심분리를 수행하고 침전물을 동결건조 시킴으로써 cell wall을 분리하였다. The dried heat-killed bacterial cells were suspended in ice cold water and ground using 0.1 mm glass beads. Unbroken cells were removed using centrifugation (1,500 × g, 4 ° C., 10 min), and only the broken cells were used as 'crude extract'. The crude extract was precipitated by centrifugation (6,500xg, 4 ° C, 30 minutes) and the precipitate was washed three times with DW. Then ribonuclease (100ug / ml) and deoxyribonuclease (50ug / ml) were added and incubated at 37 ° C for 18 hours. The cell wall was separated by centrifugation at 6,500xg for 30 minutes and lyophilization of the precipitate.
1g의 cell wall을 5% trichloroacetic acid (TCA)를 사용하여 22℃에서 18시간동안 incubation 시킨 후 원심분리를 통하여 침전 시켰다. 침전물은 acetone을 이용하여 건조시킴으로써 'peptidoglycan'을 분리하였다. 반면, supernatant는 ethyl ether를 이용한 TCA extraction을 통하여 TCA를 제거시키고 3배의 acetone을 이용하여 침전시킴으로써 'teichoic acid(TA)'를 준비하였다. 1 g of the cell wall was incubated at 22 ° C. for 18 hours using 5% trichloroacetic acid (TCA) and then precipitated by centrifugation. The precipitate was isolated by 'peptidoglycan' by drying with acetone. On the other hand, supernatant prepared 'teichoic acid (TA)' by removing TCA through TCA extraction with ethyl ether and precipitating with 3 times acetone.
Lactobacillus plantarum K8으로부터의 genomic DNA는 genomic DNA prep kit (Promega)을 사용하여 분리하였다. 또한 리포테익코익산 (lipoteichoic acid)는 Hartung (Schroder, et al., 2003. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, Lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR4 and MD-2 are not involved. J. Biol. Chem. 278:15587-15594) 등이 사용한 butanol extraction 방법을 사용하여 분리하였다.Genomic DNA from Lactobacillus plantarum K8 was isolated using genomic DNA prep kit (Promega). Lipoteichoic acid is also known as Hartung (Schroder, et al., 2003. Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR) -2, Lipopolysaccharide-binding protein ( LBP), and CD14, whereas TLR4 and MD-2 are not involved.J. Biol. Chem. 278: 15587-15594).
3-2) 유산균 구성성분의 싸이토카인에 미치는 영향3-2) Effect of Lactic Acid Bacteria on Cytokines
IL-23은 IL-12에 비해서 cytotoxic T 세포의 유지와 Th1 세포로의 분화에 있어서 IL-12에 비해서 더욱 효과가 뛰어나다는(8)것이 보고됨에 따라 Th1 cytokine으로서 발현을 조사하였으며 IL-4와 함께 중요한 Th2 cytokine IL-10의 발현량을 조사하였다. 실시예 2에서와 같이 비장세포를 분리하고 각각의 구성성분을 분리하여 처리(10ug/ml)했을 경우 생균을 처리하거나 heat-killed plantarum(108)을 처리했을 때 보다 더 높은 사이토카인의 발현을 유도하였다. 그 중에서도 순수 분리한 리포테익코익산과 테이코익산 (Teichoic acid)을 처리했을 경우 IL-23p19의 발현 양이 높게 나타났고, DNA와 crude extract를 처리할 경우에는 IL-23p19 및 TNF-a에 비해서 IL-10의 발현 level이 증가하였다 (도2).IL-23 has been reported to be more effective than IL-12 in the maintenance of cytotoxic T cells and differentiation into Th1 cells compared with IL-12 (8). Together, the expression levels of the important Th2 cytokine IL-10 were examined. As in Example 2, when the splenocytes were isolated and each component was separated and treated (10 ug / ml), the expression of cytokine was higher than that when treated with live bacteria or treated with heat-killed plantarum (10 8 ). Induced. Among them, pure lipoiccoic acid and teichoic acid were treated with IL-23p19, and DNA and crude extract were higher than IL-23p19 and TNF-a. The expression level of IL-10 was increased (FIG. 2).
본 발명의 균주 또는 균주를 배양한 배양물이나 발효식품, lipoteichoic aicd 또는 이를 함유하는 파쇄물을 섭취하였을 때, Th1 면역반응을 유도하여 아토피성 피부염, 천식, 두드러기, 과민증, 알레르기성 비염 등 알레르기성 질환을 예방 및 치료할 수 있다.Allergic diseases such as atopic dermatitis, asthma, hives, hypersensitivity, and allergic rhinitis are induced by inducing a Th1 immune response when the culture or fermented food, lipoteichoic aicd or lysate containing the same of the present invention is cultured. Can be prevented and treated.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060007968A KR100745013B1 (en) | 2006-01-25 | 2006-01-25 | Lactic acid bacteria preventing and treating allergic diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060007968A KR100745013B1 (en) | 2006-01-25 | 2006-01-25 | Lactic acid bacteria preventing and treating allergic diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070078107A true KR20070078107A (en) | 2007-07-31 |
KR100745013B1 KR100745013B1 (en) | 2007-08-10 |
Family
ID=38502504
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060007968A KR100745013B1 (en) | 2006-01-25 | 2006-01-25 | Lactic acid bacteria preventing and treating allergic diseases |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100745013B1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011025286A3 (en) * | 2009-08-26 | 2011-07-14 | 주식회사 알엔에이 | Lipoteichoic acid-derived glycolipids, and compositions comprising same |
EP2360237A1 (en) * | 2008-12-03 | 2011-08-24 | CJ CheilJedang Corporation | Novel lactobacillus plantarum and composition containing the same |
EP2455450A1 (en) * | 2009-07-14 | 2012-05-23 | CJ CheilJedang Corporation | Novel lactobacillus plantarum and composition containing same |
EP2457992A1 (en) * | 2009-07-22 | 2012-05-30 | CJ CheilJedang Corporation | Novel lactobacillus plantarum and composition comprising same |
WO2014088183A1 (en) * | 2012-12-07 | 2014-06-12 | 바이오제닉스코리아 주식회사 | Lactobacillus having ability to induce il-12 production, and method for culturing same |
KR101406168B1 (en) * | 2013-05-03 | 2014-06-13 | 씨제이제일제당 (주) | Novel lactobacillus plantarum and compositions comprising the same |
JP2018511583A (en) * | 2015-03-11 | 2018-04-26 | エムディー ヘルスケア インコーポレイテッドMd Healthcare Inc. | A composition for preventing or treating inflammatory diseases, comprising an extracellular vesicle derived from lactic acid bacteria as an active ingredient |
US10676708B2 (en) | 2014-09-30 | 2020-06-09 | Rna Inc. | Method for preparing microbial preparation and microbial preparation produced by the same |
WO2024107012A1 (en) * | 2022-11-17 | 2024-05-23 | 주식회사 지아이바이옴 | Lactiplantibacillus plantarum strain, culture medium derived therefrom, and antiallergic uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI277651B (en) | 2002-09-02 | 2007-04-01 | Genmont Biotech Inc | New use of some lactobacillus strains in treating allergy |
-
2006
- 2006-01-25 KR KR1020060007968A patent/KR100745013B1/en active IP Right Grant
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2360237A4 (en) * | 2008-12-03 | 2013-01-23 | Cj Cheiljedang Corp | Novel lactobacillus plantarum and composition containing the same |
EP2360237A1 (en) * | 2008-12-03 | 2011-08-24 | CJ CheilJedang Corporation | Novel lactobacillus plantarum and composition containing the same |
US20110312061A1 (en) * | 2008-12-03 | 2011-12-22 | Cj Cheiljedang Corp. | Novel lactobacillus plantarum and composition containing the same |
JP2012510291A (en) * | 2008-12-03 | 2012-05-10 | シージェイ チェイルジェダン コーポレーション | Novel Lactobacillus plantarum and composition containing the same |
US9962418B2 (en) | 2008-12-03 | 2018-05-08 | Cj Cheiljedang Corp. | Lactobacillus plantarum and composition containing the same |
US9572845B2 (en) * | 2008-12-03 | 2017-02-21 | Cj Cheiljedang Corp. | Lactobacillus plantarum and composition containing the same |
EP2455450A1 (en) * | 2009-07-14 | 2012-05-23 | CJ CheilJedang Corporation | Novel lactobacillus plantarum and composition containing same |
JP2012533290A (en) * | 2009-07-14 | 2012-12-27 | シージェイ チェイルジェダン コーポレーション | Novel Lactobacillus plantarum and composition containing the same |
KR101255050B1 (en) * | 2009-07-14 | 2013-04-16 | 씨제이제일제당 (주) | Novel lactobacillus plantarum and compositions comprising the same |
EP2455450A4 (en) * | 2009-07-14 | 2013-01-09 | Cj Cheiljedang Corp | Novel lactobacillus plantarum and composition containing same |
EP2457992A1 (en) * | 2009-07-22 | 2012-05-30 | CJ CheilJedang Corporation | Novel lactobacillus plantarum and composition comprising same |
EP2457992A4 (en) * | 2009-07-22 | 2013-01-09 | Cj Cheiljedang Corp | Novel lactobacillus plantarum and composition comprising same |
AU2009350208B2 (en) * | 2009-07-22 | 2014-08-07 | Cj Cheiljedang Corp. | Novel Lactobacillus plantarum and composition comprising same |
KR101486999B1 (en) * | 2009-07-22 | 2015-01-28 | 씨제이제일제당 주식회사 | Novel lactobacillus plantarum and compositions comprising the same |
JP2012533319A (en) * | 2009-07-22 | 2012-12-27 | シージェイ チェイルジェダン コーポレーション | Novel Lactobacillus plantarum and composition containing the same |
US10842833B2 (en) | 2009-07-22 | 2020-11-24 | Cj Cheiljedang Corp. | Lactobacillus plantarum and composition comprising same |
US11759486B2 (en) | 2009-07-22 | 2023-09-19 | Cj Cheiljedang Corp. | Lactobacillus plantarum and composition comprising same |
WO2011025286A3 (en) * | 2009-08-26 | 2011-07-14 | 주식회사 알엔에이 | Lipoteichoic acid-derived glycolipids, and compositions comprising same |
WO2014088183A1 (en) * | 2012-12-07 | 2014-06-12 | 바이오제닉스코리아 주식회사 | Lactobacillus having ability to induce il-12 production, and method for culturing same |
KR101406168B1 (en) * | 2013-05-03 | 2014-06-13 | 씨제이제일제당 (주) | Novel lactobacillus plantarum and compositions comprising the same |
US10676708B2 (en) | 2014-09-30 | 2020-06-09 | Rna Inc. | Method for preparing microbial preparation and microbial preparation produced by the same |
JP2018511583A (en) * | 2015-03-11 | 2018-04-26 | エムディー ヘルスケア インコーポレイテッドMd Healthcare Inc. | A composition for preventing or treating inflammatory diseases, comprising an extracellular vesicle derived from lactic acid bacteria as an active ingredient |
WO2024107012A1 (en) * | 2022-11-17 | 2024-05-23 | 주식회사 지아이바이옴 | Lactiplantibacillus plantarum strain, culture medium derived therefrom, and antiallergic uses thereof |
Also Published As
Publication number | Publication date |
---|---|
KR100745013B1 (en) | 2007-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100745013B1 (en) | Lactic acid bacteria preventing and treating allergic diseases | |
TWI592487B (en) | Novel lactobacillus paracasei subsp. paracasei k56 | |
KR101255050B1 (en) | Novel lactobacillus plantarum and compositions comprising the same | |
KR101075557B1 (en) | Novel Lactobacillus plantarum and compositions comprising the same | |
CN105579574B (en) | Novel lactic acid bacteria and medicine, diet product and feed containing novel lactic acid bacteria | |
US8372392B2 (en) | Lactobacillus paracasei strain LT12 as immunity regulatory agent | |
KR102698401B1 (en) | Salt-tolerant lactic acid bacteria, method for culturing salt-tolerant lactic acid bacteria, and immunostimulant | |
CN104894021A (en) | Lactobacillus paracasei strain and application thereof | |
US11667977B2 (en) | Method of using a medication or a food supplement with lactobacillus strains isolated from kimere for strengthining the immune system | |
CN111676171B (en) | Probiotic for excessive crying of infants | |
Takeda et al. | Effects of oral administration of probiotics from Mongolian dairy products on the Th1 immune response in mice | |
KR101075558B1 (en) | Novel Lactobacillus plantarum and compositions comprising the same | |
CN102309001B (en) | Food composition and medicinal composition of lactobacillus strain for treating allergy | |
CN1329505C (en) | Microorganism strain GM-090 of lactobacillus fermentum and its use for stimulating INF-y secretion and/or treating allergy | |
TWI674101B (en) | Method for preparing lemon fermentation product and use thereof | |
Kumagai et al. | Lactobacillus paracasei K71 isolated from Sakekasu (Sake lees) suppresses serum IgE levels in ovalbumin-immunized Balb/c mice | |
KR20040019669A (en) | Korean Isolate Bifidobacterium infantis PL9506 with High Nutraceutical Activity | |
KR101311989B1 (en) | Products containing Lactobacillus casei HY7211 having immuno-regulatory and immuno-stimulatory functions as effective component | |
TW202237814A (en) | Lactobacillus delbrueckii subsp. lactis ldl557 isolate and uses of the same | |
KR20020034261A (en) | Lactobacillus rhamnosus strain and uses thereof | |
KR20150018012A (en) | Lactobacillus plantarum and use thereof | |
KR20160078688A (en) | Manufacturing method of probiotics powder containing goat milk | |
KR100725012B1 (en) | The new lactobacillus acidophilus HY 7036 isolated from korean adult, having high constipation improvement effect, high relieving intestinal disorders and high organic acid producibility, and products containing it | |
Kimoto-Nira et al. | A derivative of Lactococcus lactis strain H61 with less interleukin-12 induction has a different cell wall | |
KR20240082209A (en) | Lactiplantibacillus plantarum strain, culture medium from thereof and anti-allergic uses of thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Publication of correction | ||
FPAY | Annual fee payment |
Payment date: 20120726 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20130724 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20141230 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20151016 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160718 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180426 Year of fee payment: 11 |
|
R401 | Registration of restoration | ||
FPAY | Annual fee payment |
Payment date: 20180808 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190723 Year of fee payment: 13 |